Journal
MOLECULAR AND CLINICAL ONCOLOGY
Volume 15, Issue 3, Pages -Publisher
SPANDIDOS PUBL LTD
DOI: 10.3892/mco.2021.2341
Keywords
galectin-1; serum autoantibody; hepatocellular carcinoma; lung cancer; enzyme-linked immunosorbent assay
Categories
Funding
- Ministry of Education, Culture, Sports, Science and Technology of Japan [24591961, 21591717]
- Grants-in-Aid for Scientific Research [24591961, 21591717] Funding Source: KAKEN
Ask authors/readers for more resources
This study evaluated serum galectin-1 antibodies in different cancer types and found that patients with hepatocellular carcinoma and lung cancer had significantly higher positive rates, suggesting the potential utility of s-GAL-1-Abs in these specific cancer types.
Although serum galectin-1 antibodies (s-GAL-1-Abs) have been evaluated in a small number of patients with cancer, a large series of patients with different cancer types have not been reported. The current study evaluated 1,833 patients with esophageal cancer (n=172), gastric cancer (n=317), colorectal cancer (n=262), hepatocellular carcinoma (n=91), prostate cancer (n=358), breast cancer (n=364), lung cancer (n=269) and 72 healthy individuals. s-GAL-1-Abs levels were analyzed using an originally developed ELISA system. A cut-off optical density value was determined as the mean (0.053) + 3 standard deviations (0.105) of sera from healthy controls. The results revealed that the positive rate of s-GAL-1-Abs in patients with hepatocellular carcinoma (16.7%) and lung cancer (13.8%) were significantly higher compared with the other groups: Esophageal cancer (11.6%), colorectal cancer (11.5%), prostate cancer (7.3%), gastric cancer (6.9%), breast cancer (6.9%) and healthy controls (4.2%). Although the positive rates of s-GAL-1-Abs in different cancer types were relatively low, s-GAL-1-Abs may be useful for patients with hepatocellular carcinoma and lung cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available